<DOC>
	<DOCNO>NCT00000896</DOCNO>
	<brief_summary>The purpose study examine level HIV reduce blood anti-HIV therapy initiate . This study also evaluate whether add GM-CSF IL-12 anti-HIV drug regimen increase rate HIV reduce . The anti-HIV drug use study include lamivudine ( 3TC ) , zidovudine ( ZDV ) , indinavir ( IDV ) , nevirapine ( NVP ) , stavudine ( d4T ) . All use successfully treat HIV . GM-CSF use treat certain blood disorder ; use experimental drug study . IL-12 ( interleukin-12 ) protein find naturally body think boost immune system . Although GM-CSF IL-12 direct effect HIV , drug may improve ability immune system fight virus .</brief_summary>
	<brief_title>A Study Compare Effectiveness Four Drug Anti-HIV Regimen Given Alone Combination With GM-CSF IL-12 HIV-Positive Patients</brief_title>
	<detailed_description>Potent antiretroviral therapy suppress HIV replication permit mathematical modeling dynamic HIV infection clearance measurement decay viral load plasma . When de nova infection block antiretroviral therapy , viral load decrease exponentially short initial lag time ( `` shoulder '' ) . This rapid decline follow slow second-phase decay . The intent study utilize four antiretroviral agent ( zidovudine , lamivudine , nevirapine , indinavir ) frequent measure viral load explore drug-specific kinetics `` shoulder '' . The decay long-lived HIV-infected tissue macrophage think major determinant slow second phase . Further , study intend use immune modulating agent potential increase turnover infect macrophage , GM-CSF IL-12 , accelerate second phase viral decay . Patients assign Group A ( 16 patient ) Group B ( 8 patient ) . Patients Group A randomize 1 follow 4 initial treatment arm : ARM A : Final dose combination ( FDC ) Zidovudine ( ZDV ) /Lamivudine ( 3TC ) . ARM B : Nevirapine ( NVP ) . ARM C : Indinavir ( IDV ) . ARM D : FDC ZDV/3TC plus NVP plus IDV . The initial regimen maintain first 72 hour blood viral dynamic evaluation collect patient maintain inpatient . Then , patient Arms A , B , C initiate FDC ZDV/3TC plus NVP plus IDV . Patients assign Group B begin follow 4-drug regimen Day 0 : ARM E : FDC ZDV/3TC plus NVP plus IDV . On Day 7 , patient Groups A B randomize receive one follow therapy addition 4-drug regimen : ARM F : GM-CSF daily 2 week , thrice weekly ( MWF ) . ARM G : IL-12 twice weekly . ARM H : No immune modulation . Patients may hospitalize initiate immune modulation may treat outpatient . Immune modulation discontinue Week 14 . Patients maintain 4-drug regimen Week 48 . [ AS PER AMENDMENT 6/11/99 : The study duration extend 96 week . ] Hepatitis A vaccine ( inactivate ) administer Weeks 16 40 [ AS PER AMENDMENT 2/13/98 : patient whose baseline hepatitis A serology negative ] .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have CD4 cell count great equal 300 cells/ml within 30 day prior study entry . Have plasma viral load ( level HIV blood ) great equal 20,000 copies/ml within 30 day study entry . Are least 18 year old . Agree practice abstinence use effective method birth control study . Exclusion Criteria You eligible study : Have take antiHIV medication 7 day . Have know seroconversion within 6 month prior study entry . Have infection require treatment within 30 day prior study entry . Have fever 7 day row 30 day study entry . Have cancer require chemotherapy . Are pregnant breastfeeding . Are take certain medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Interleukin-12</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>